ENaC as a Novel Mechanism for Hypertension and Volume Expansion in Type 2 Diabetes

NCT01804777 EARLY_PHASE1 TERMINATED

The purpose of this study is to determine with the administration of amiloride, observe an enhanced natriuresis, reduction in blood pressure and weight compared to the administration of hydrochlorothiazide in Type 2 Diabetics.

Details

Lead sponsor	University of New Mexico
Phase	EARLY_PHASE1
Status	TERMINATED
Enrolment	9
Start date	2013-03
Completion	2014-12

Conditions

• Proteinuria
• Hypertension
• Type II Diabetes

Interventions

• Amiloride
• HCTZ

Primary outcomes

• Blood Pressure — one month
  Change in clinic systolic BP. This BP measure will be the average of three serial BP measurements taken one minute apart after 5 minutes of sitting quietly.

Countries

United States